Nootropic Peptides Compared: Semax, Selank, and Cerebrolysin

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

Three Peptides, Three Approaches to Cognitive Research

If you’ve been following the research peptide space, you’ve probably noticed that three names keep coming up whenever the conversation turns to cognitive function: Semax, Selank, and Cerebrolysin. They’re often mentioned in the same breath, lumped together as “nootropic peptides” — but that’s a bit like calling a scalpel, a bandage, and an antibiotic “medical tools.” Technically accurate, but it misses the point entirely. Each of these compounds works through fundamentally different mechanisms, targets different aspects of neural function, and has generated its own distinct body of research.

So let’s break them down properly — what they are, how they differ, what the research actually shows, and why researchers tend to study them in different contexts. Whether you’re designing a study or just trying to understand the landscape, this comparison should help clarify which peptide does what and why the distinctions matter.

Semax: The BDNF Amplifier

What It Is

Semax is a synthetic heptapeptide — seven amino acids long — with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a modified fragment of adrenocorticotropic hormone (ACTH). Specifically, it’s based on ACTH(4-10), the segment of the ACTH molecule associated with cognitive effects rather than the adrenal-stimulating properties of the full hormone. The key modification was the addition of a Pro-Gly-Pro tripeptide at the C-terminus, which dramatically increases the molecule’s metabolic stability and extends its duration of action from minutes to hours.

This is an important distinction: Semax was deliberately engineered to retain the neurotrophic effects of the ACTH fragment while eliminating its hormonal activity. It doesn’t stimulate cortisol production. It doesn’t affect the adrenal axis. What it does — according to a substantial body of preclinical research — is influence the expression of neurotrophic factors in the brain.

The BDNF Connection

Brain-Derived Neurotrophic Factor (BDNF) is often called the brain’s fertilizer, and for good reason. It’s a protein that supports the survival of existing neurons, encourages the growth and differentiation of new neurons and synapses, and plays a critical role in long-term memory formation. Low BDNF levels have been associated with depression, cognitive decline, and neurodegenerative conditions in observational research.

Semax’s most well-documented effect in preclinical research is its ability to increase BDNF expression. A study published by researchers including Dolotov and colleagues showed that a single intranasal application of Semax at 50 micrograms per kilogram produced a rapid increase in BDNF protein levels in the rat basal forebrain within three hours. More detailed work demonstrated that Semax produced a 1.4-fold increase in BDNF protein alongside a 1.6-fold increase in TrkB receptor phosphorylation — the receptor through which BDNF exerts its effects — and a 3-fold increase in exon III BDNF mRNA in the hippocampus.

But BDNF isn’t the only neurotrophic factor affected. Research by Dolotov, Eremin, and colleagues at the Institute of Molecular Genetics found that Semax also enhances the transcription of Nerve Growth Factor (NGF) and Neurotrophin-3 (NT-3) in models of cerebral ischemia. After middle cerebral artery occlusion in rats, Semax enhanced the transcription of BDNF at 3 hours post-occlusion, and NGF at 24 and 72 hours, suggesting a temporally coordinated neurotrophic response rather than a simple blanket upregulation.

Beyond Neurotrophins: Genomic Effects

A genome-wide transcriptional analysis of Semax’s effects on rat brain focal ischemia revealed something surprising — Semax affected the expression of genes related not just to neurotrophic signaling, but also to immune function and vascular biology. The study identified changes in genes involved in inflammatory response modulation, suggesting that Semax’s neuroprotective effects may involve anti-inflammatory mechanisms in addition to its neurotrophic actions. This broader genomic perspective has expanded the research framework around Semax beyond a simple “BDNF booster” narrative.

Administration and Bioavailability

Semax is typically administered intranasally in research settings, a route that leverages the olfactory and trigeminal nerve pathways to deliver the peptide more directly to the brain. This route bypasses the blood-brain barrier to a degree that would be difficult to achieve with systemic administration of a peptide this size. The intranasal route also avoids gastrointestinal degradation and first-pass hepatic metabolism, both of which would rapidly destroy a peptide administered orally.

For more on Semax’s mechanisms and research, see our detailed Semax Research Guide.

Selank: The Anxiolytic Immunomodulator

What It Is

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed at the same Russian research institute as Semax, but with a completely different starting point. While Semax is derived from ACTH, Selank is based on tuftsin — an endogenous tetrapeptide (Thr-Lys-Pro-Arg) that is a natural fragment of the heavy chain of immunoglobulin G. Like Semax, Selank was stabilized with the addition of a Pro-Gly-Pro tripeptide at the C-terminus to extend its biological half-life.

This immunological origin is critical for understanding Selank’s unique profile. It sits at the intersection of the immune system and the nervous system — a crossroads that has become increasingly important as research has revealed the deep interconnections between inflammation, immune signaling, and brain function.

The GABAergic Mechanism

Selank’s anxiolytic effects appear to be mediated primarily through the GABAergic system — the brain’s major inhibitory neurotransmitter network. Research has demonstrated that Selank can modulate the expression of genes involved in GABAergic neurotransmission. A study published in Frontiers in Pharmacology found that Selank affects the expression of genes encoding GABA-A receptor subunits, potentially altering the receptor’s sensitivity to GABA and producing anxiolytic effects comparable to low-dose benzodiazepines — but without the sedation, cognitive impairment, or addiction risk that characterize benzodiazepine use.

This is a crucial distinction in the research context. Benzodiazepines work by directly binding to the GABA-A receptor and potentiating GABA’s inhibitory effects, which is effective for anxiety but comes with well-documented problems including tolerance, dependence, and cognitive blunting. Selank appears to modulate the GABAergic system at the gene expression level — a fundamentally different and potentially more nuanced mechanism of action that has attracted considerable research interest.

A preclinical study demonstrated that Selank enhances the anxiolytic effect of diazepam under conditions of unpredictable chronic mild stress in rats, suggesting a synergistic interaction with GABAergic signaling. The combination produced greater anxiety reduction than either compound alone, pointing to a mechanism that complements rather than duplicates benzodiazepine pharmacology.

Immunomodulatory Properties

Selank’s tuftsin-derived structure gives it inherent immunomodulatory properties that distinguish it from purely neurological compounds. Research has documented effects on cytokine balance, with Selank influencing the production of IL-6, IL-10, and other cytokines involved in the inflammatory response. This dual neuro-immune profile is particularly relevant given the growing body of research linking peripheral inflammation to anxiety and mood disorders — a field sometimes called “immunopsychiatry.”

The immunomodulatory dimension also means that Selank’s effects in research models of anxiety may partially operate through anti-inflammatory mechanisms rather than exclusively through direct neuronal signaling. This multi-pathway action makes Selank a compound of interest for researchers studying the neuroimmune interface and the role of peripheral immune signaling in psychiatric conditions.

Cognitive Effects

While Selank is primarily studied for its anxiolytic properties, research has also documented nootropic effects including influences on learning and memory processes. Interestingly, Selank has also been shown to protect against ethanol-induced memory impairment in rats by regulating BDNF content in the hippocampus and prefrontal cortex — demonstrating that its neuroprotective repertoire extends beyond anxiety reduction into cognitive territory, though through different mechanisms than Semax.

For more details, see our Selank Research Guide.

Cerebrolysin: The Neurotrophic Mixture

What It Is

Cerebrolysin is fundamentally different from Semax and Selank in that it is not a single synthetic peptide but rather a standardized mixture of low-molecular-weight neuropeptides and free amino acids derived from purified porcine (pig) brain proteins. The manufacturing process involves controlled enzymatic proteolysis of pig brain tissue, yielding a complex biological preparation containing multiple neurotrophic factors, peptide fragments, and amino acids — over 200 distinct molecular components by some analyses.

This complexity is both Cerebrolysin’s strength and its methodological challenge. The preparation mimics the natural neurotrophic environment of the brain more closely than any single synthetic peptide can, but it also makes precise mechanistic attribution more difficult. When Cerebrolysin produces a biological effect, it can be challenging to determine which specific component or combination of components is responsible.

Neurotrophic Factor Mimicry

Cerebrolysin’s biological activity is attributed to its capacity to mimic the actions of endogenous neurotrophic factors, particularly BDNF, NGF, and Ciliary Neurotrophic Factor (CNTF). Unlike Semax, which upregulates the body’s own production of neurotrophins, Cerebrolysin is thought to directly provide neurotrophic-like activity through its peptide components. Research comparing Cerebrolysin and Semax in cultured rat pheochromocytoma (PC12) cells found that Cerebrolysin improved cell survival in serum-free medium and reduced apoptotic cells from 32% to 10%, while Semax produced no such trophic effect — suggesting that their neuroprotective mechanisms are fundamentally different.

This finding is important: Cerebrolysin appears to exert direct trophic support, while Semax’s neuroprotective effects are mediated through indirect mechanisms, likely involving the upregulation of endogenous neurotrophic factor expression. Both approaches result in neuroprotection, but through distinct biological pathways.

Clinical Research: The CARS and CAPTAIN Trials

Cerebrolysin has the most extensive clinical research portfolio of the three compounds discussed here. The Cerebrolysin and Recovery After Stroke (CARS) trials — coordinated by Dr. Dafin Muresanu — were prospective, randomized, double-blind, placebo-controlled multicenter studies that evaluated 30 mL Cerebrolysin administered daily for 21 days alongside standardized rehabilitation in post-stroke patients. The combined CARS meta-analysis assessed the efficacy of Cerebrolysin on motor recovery during early rehabilitation.

The CAPTAIN (Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery) program extended this research to traumatic brain injury, evaluating Cerebrolysin’s effects on functional outcomes in moderate-to-severe TBI patients. A systematic review and meta-analysis of twelve randomized controlled trials examining Cerebrolysin safety for neurorecovery after acute ischemic stroke concluded that the compound demonstrated a favorable safety profile in this context.

Additional research has investigated Cerebrolysin in the context of vascular dementia, with a Cochrane systematic review examining the available evidence for this application. While the evidence base continues to develop, these clinical studies represent a level of formal clinical investigation that has not yet been achieved for Semax or Selank in Western research settings.

For a deeper dive, see our Cerebrolysin Research Guide.

Head-to-Head Comparison

Now that we’ve covered each compound individually, let’s put them side by side so the differences — and similarities — are clear:

Feature	Semax	Selank	Cerebrolysin
Type	Synthetic heptapeptide	Synthetic heptapeptide	Porcine-derived peptide mixture
Origin	ACTH(4-10) fragment	Tuftsin (IgG fragment)	Enzymatic proteolysis of pig brain
Primary Mechanism	BDNF/neurotrophin upregulation	GABAergic modulation + immunomodulation	Direct neurotrophic factor mimicry
BDNF Effect	Strong upregulation (1.4x protein, 3x mRNA)	Indirect (via BDNF regulation in hippocampus)	Mimics BDNF-like activity directly
Primary Research Focus	Cognitive enhancement, neuroprotection	Anxiolysis, stress response	Stroke recovery, TBI, neurodegeneration
Administration Route	Intranasal (research)	Intranasal (research)	Intravenous / intramuscular
Immune Effects	Secondary (via gene expression)	Primary (tuftsin-derived immunomodulation)	Secondary (anti-inflammatory)
Anxiolytic Properties	Not primary focus	Primary focus (GABA-mediated)	Not primary focus
Clinical Trial Status	Approved in Russia; limited Western trials	Approved in Russia; limited Western trials	Multiple Western RCTs (CARS, CAPTAIN)
Molecular Complexity	Single defined molecule	Single defined molecule	200+ molecular components

How Researchers Choose Between Them

The choice between these three compounds in a research setting isn’t really about which one is “better” — it’s about which mechanism is most relevant to the research question being asked.

If the question involves neurotrophic factor regulation — how BDNF expression is controlled, what happens when neurotrophin levels are increased in specific brain regions, or how endogenous neurotrophic support affects neuronal survival after injury — Semax is typically the compound of choice. Its well-characterized effect on BDNF/NGF transcription makes it a useful pharmacological tool for probing neurotrophic signaling pathways.

If the question involves anxiety, stress response, or neuroimmune interactions — how GABAergic tone affects anxiety-like behavior, whether immune modulation can influence psychiatric phenotypes, or how anxiolytic effects can be achieved without benzodiazepine-like mechanisms — Selank offers a unique pharmacological profile that addresses these questions specifically.

If the question involves acute neuroprotection or neurorecovery — whether neurotrophic support can improve outcomes after stroke or traumatic brain injury, how a complex neurotrophic environment affects neuronal survival and plasticity — Cerebrolysin’s clinical evidence base and direct trophic activity make it the most relevant choice.

Many research programs study multiple compounds from this group, either in parallel or in combination, to dissect the relative contributions of different neuroprotective mechanisms. The fact that Semax (endogenous neurotrophin upregulation), Selank (GABAergic/immune modulation), and Cerebrolysin (direct neurotrophic support) work through non-overlapping pathways makes them complementary tools in the neuroscience research toolkit.

The Broader Nootropic Peptide Landscape

These three compounds don’t exist in isolation. The research peptide landscape includes several other molecules studied for cognitive or neuroprotective effects that are worth knowing about for context:

PE-22-28 is a synthetic peptide derived from the neuropeptide PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide). It has been investigated for cognitive-enhancing effects in preclinical models, potentially working through adenylate cyclase activation and cAMP signaling — yet another distinct mechanism from the three compounds compared here.

Together, these compounds represent different pharmaceutical approaches to the same fundamental question: how can neural function be supported, protected, and potentially enhanced through targeted peptide-based interventions? The diversity of mechanisms reflects the complexity of the brain itself — no single pathway governs cognition, and no single compound is likely to address all aspects of neural function.

What the Research Still Needs

Despite the promising preclinical data and Cerebrolysin’s clinical trial portfolio, there are important gaps in the research that are worth acknowledging:

Head-to-head comparative studies are rare. While each compound has its own body of research, direct comparisons under identical experimental conditions are uncommon. The PC12 cell study comparing Cerebrolysin and Semax is one of the few examples, and more systematic comparisons would significantly advance the field.

Western clinical trials for Semax and Selank are limited. Both compounds are approved medications in Russia, but the clinical evidence base accessible to Western researchers consists primarily of preclinical studies and Russian-language clinical reports. Larger, Western-standard randomized controlled trials would strengthen the evidence for these compounds considerably.

Combination studies are virtually nonexistent. Given that these compounds work through complementary mechanisms, research examining whether combinations produce additive or synergistic effects would be scientifically valuable — but such studies have not yet been conducted in any systematic way.

Long-term effects are understudied. Most research has examined acute or short-term administration. The effects of chronic exposure — including potential receptor adaptations, tolerance, or sustained neuroplastic changes — remain largely uncharacterized for all three compounds.

These gaps represent opportunities for future research and underscore the importance of continuing to investigate these compounds with rigorous experimental designs and transparent reporting.

Summary of Key Research References

Study	Year	Type	Focus	Reference
Dolotov et al.	2006	Preclinical	Semax increases BDNF protein in rat basal forebrain	PubMed 16635254
Dolotov et al.	2006	Preclinical	Semax regulates BDNF and TrkB expression in rat hippocampus	PubMed 16996037
Filippenkov et al.	2024	Preclinical	Semax and PGP activate neurotrophin transcription after cerebral ischemia	PMC11498467
Andreeva et al.	2014	Genomic Analysis	Semax effects on immune and vascular gene expression in focal ischemia	PMC3987924
Kasian et al.	2016	Preclinical	Selank effects on GABAergic neurotransmission genes	PMC4757669
Semenova et al.	2017	Preclinical	Selank enhances diazepam anxiolytic effect under chronic stress	PMC5322660
Muresanu et al.	2016	RCT (CARS)	Cerebrolysin and recovery after stroke	PMC4689177
Zhang et al.	2022	Meta-Analysis	Cerebrolysin safety for neurorecovery after ischemic stroke	PMC8708612
Gavrilova et al.	2019	Cochrane Review	Cerebrolysin for vascular dementia	PMC6844361

---

Research Disclaimer

For laboratory and research use only. Not for human consumption.

This article is intended solely as a summary of published scientific research. It does not constitute medical advice, treatment recommendations, or an endorsement for any therapeutic purpose. The research discussed herein is predominantly preclinical, and results may not translate to human outcomes. Researchers should consult relevant institutional review boards and regulatory guidelines before designing studies involving these compounds.

NorthPeptide supplies research-grade peptides for legitimate scientific investigation. All products are sold strictly for laboratory and research purposes.